ArticleIranian journal of pharmaceutical research : IJPR2012
Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in iran.
Article in Iranian journal of pharmaceutical research : IJPR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Utilization of prospective, pharmacist-driven restriction criteria to improve appropriateness of empiric intravenous vancomycin use.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Drug Utilization Evaluation (DUE) of vancomycin: A cross-sectional study.Annals of medicine and surgery (2012) · 2022Article
- Compliance with Antibiotics Prophylaxis Guideline in Surgical Patients in ICUs of a Teaching Referral Hospital.Health services insights · 2022Article
- Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters.Frontiers in pharmacology · 2022Article
- A simple and validated HPLC method for vancomycin assay in plasma samples: the necessity of TDM center development in Southern Iran.Research in pharmaceutical sciences · 2020Article
- A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.Infection and drug resistance · 2020Review
- Comparison of Ceftizoxime Plus Ampicillin-Sulbactam versus Gentamicin Plus Ampicillin-Sulbactam in the Prevention of Post-Transplant Early Bacterial Infections in Liver Transplant Recipients: A Randomized Controlled Trial.Infection and drug resistance · 2020Article
- Curcumin Supplementation Alleviates Polymyxin E-Induced Nephrotoxicity.Journal of experimental pharmacology · 2020Article
- Drug Utilization Evaluation of Vancomycin among Patients in Jafar Ibn Auf Pediatric Hospital, 2018.F1000Research · 2019Article
- Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran.Drug, healthcare and patient safety · 2018Article
- Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Article
- Drug utilization evaluation of imipenem and intravenous ciprofloxacin in a teaching hospital.Iranian journal of pharmaceutical research : IJPR · 2013Article
- Vancomycin Pharmacokinetic Parameters in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT).International journal of hematology-oncology and stem cell research · 2013Article
- Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to evaluate the pattern of vancomycin administration in the hematology-oncology ward of Nemazee Hospital, Shiraz, Iran. Study criteria were developed to assess the several parameters involved in vancomycin therapy. These parameters include the appropriateness of drug usage, dosage, duration of therapy, monitoring for toxicity and serum concentration monitoring. The serum concentration was measured by an automated Fluorescence Polarization Immunoassay. Clinical and preclinical parameters such as Glomerular Filtration Rate (GFR), microbial culture, antibacterial sensitivity, WBC count and fever were collected and recorded for analysis. Sixty patients were enrolled in the study, consisting of 45 males and 15 females. The age range was 15 to 68 years. In this study, 68.63% of the vancomycin used for the patients with febrile neutropenia was compatible with the Infectious Disease Society of America (IDSA) guideline. The initial dosage of vancomycin in 68.63%, rate of infusion in 100%, and dilution of vancomycin in100%, were appropriate. Inappropriate use was more evident in the continuation of vancomycin in 50% of the patients. No appropriate dosage adjustment was done for 50% of the patients with increased serum creatinine. Based on the results, the indication of vancomycin in febrile neutropenia was satisfactory. However, there were some required factors such as continuation of vancomycin, adjustment of dosage or interval, microbial culture, antibiotic sensitivity test before the first dose administration, measurement of serum concentration and monitoring which had to be revised in order to achieve an effective treatment.
Indexed as
Identifiers
24250438PMC3813098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.